Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Tenalisib is an inhibitor of PI3Kδ and PI3Kγ (IC50s = 24.5 and 33.2 nM, respectively).1 It is greater than 300- and 120-fold selective for PI3Kδ and PI3Kγ, respectively, over PI3Kα and PI3Kβ. Tenalisib (10 µM) induces cell death in L-540, KM-H2, and L-428 Hodgkin lymphoma cells. It induces cell cycle arrest at the G0/G1 phase in the same cells. In vivo, tenalisib reduces tumor growth and vasculature, induces tumor necrosis, and induces the M1 phenotype in tumor-associated macrophages (TAMs) in an L-540 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530. Clin. Cancer Res. 25(3), 1098-1112 (2019).